AX9.F Akebia Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
0.4747 EUR
Close of Nov 11, 2026
0.3601 1.55
Market cap
EUR 132M
P/E
-
P/B
7.18x
ROE
-211.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AX9.F undervalued?

Graham number

The Graham number of Akebia Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Akebia Therapeutics Inc fundamental analysis

No fundamental analysis for Akebia Therapeutics Inc yet.

Akebia Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in…

Full company profile